Amgen psoriatic arthritis drug maintains efficacy after 1 yr -study

June 11, 2014 9:03 PM

7 0

June 11 (Reuters) - A drug being developed by Amgen Inc for psoriatic arthritis demonstrated sustained effectiveness after a year of treatment with no new safety concerns, according to data from a midstage trial.

Amgen and partner AstraZeneca Plc had previously presented 12-week data from the 168-patient trial of the biotech drug, brodalumab, showing it to be significantly more effective than a placebo.

Also read: Bayer says asbestos-related tumor treatment misses key goal

Read more

To category page